# US 2016/0206578 A1 · Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0206578 A1
- Document ID: US20160206578A1
- Status: Published application
- Kind: A1
- Application number: 15/075,356
- Filed: 2016-03-21
- Published: 2016-07-21
- Earliest claimed: 2008-09-19
- Assignees: PIMCO 2664 Limited
- Applicants: PIMCO 2664 Limited
- Inventors: Iain Robert Greig; Rose Mary Sheridan; Raymond Fisher; Matthew John Tozer; Juha Andrew Clase; Andrew Smith; Andrew Robert Tuffnell; Robert Jurgen Van't Hof
- Web page: https://patentgrep.com/patent/US20160206578A1

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07C 311/20: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 311/28: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 207/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 213/34: to which a second hetero atom is attached
- C07D 213/52: Sulfur atoms
- C07D 213/61: Halogen atoms or nitro radicals
- C07D 239/26: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 239/30: Halogen atoms or nitro radicals
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.

## Claims

### Claim at position 1

1-289. (canceled)

### Claim 290

A method of treatment of rheumatoid arthritis in a patient in need of said treatment comprising administering to said patient a therapeutically effective amount of a compound selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein:
either: ═W— is —CH═ and —Y═ is —CH═;
or: ═W— is —CH═ and —Y═ is —N═;
—RX2 is —RX2S;
—RX4 is —RX4S;
RX2S is —RX;
RX4S is —RX;
each —RX is independently —F, —Cl, —Br, —I, —RXX, —OH, —ORXX, —SRXX, —CF3, —OCF3, —CN, or —NO2;
each —RX is independently saturated aliphatic C1-4 alkyl;
—RXC1 is independently —H or —RXCC;
—RXC2 is independently —H;
—RXCC is independently —F, —Cl, or —RXCCC;
—RXCCC is independently -Me or -Et;
—RSN is —H;
-DQ is -D1-Q1;
either: -D1 is cyclohexane-1,4-di-yl;
or: -D1- is 4-methyl-cyclohexane-1,4-di-yl; and
-Q1 is —OH.

### Claim 291 (depends on 290)

A method according to claim 290, wherein ═W— is —CH═ and —Y═ is —CH═.

### Claim 292 (depends on 290)

A method according to claim 290, wherein ═W— is —CH═ and —Y═ is —N═.

### Claim 293 (depends on 291)

A method according to claim 291, wherein -D1 is cyclohexane-1,4-di-yl.

### Claim 294 (depends on 292)

A method according to claim 292, wherein -D1 is cyclohexane-1,4-di-yl.

### Claim 295 (depends on 291)

A method according to claim 291, wherein -D1 is 4-methyl-cyclohexane-1,4-di-yl.

### Claim 296 (depends on 292)

A method according to claim 292, wherein -D1 is 4-methyl-cyclohexane-1,4-di-yl.

### Claim 297 (depends on 293)

A method according to claim 293, wherein —RXC1 is —H.

### Claim 298 (depends on 294)

A method according to claim 294, wherein —RXC1 is —H.

### Claim 299 (depends on 295)

A method according to claim 295, wherein —RXC1 is —H.

### Claim 300 (depends on 296)

A method according to claim 296, wherein —RXC1 is —H.

### Claim 301 (depends on 293)

A method according to claim 293, wherein —RXC1 is —RXCC; and —RXCC is —F.

### Claim 302 (depends on 294)

A method according to claim 294, wherein —RXC1 is —RXCC; and —RXCC is —F.

### Claim 303 (depends on 295)

A method according to claim 295, wherein —RXC1 is —RXCC; and —RXCC is —F.

### Claim 304 (depends on 296)

A method according to claim 296, wherein —RXC1 is —RXCC; and —RXCC is —F.

### Claim 305 (depends on 293)

A method according to claim 293, wherein —RXC1 is —RXCC; and —RXCC is —Cl.

### Claim 306 (depends on 294)

A method according to claim 294, wherein —RXC1 is —RXCC; and —RXCC is —Cl.

### Claim 307 (depends on 295)

A method according to claim 295, wherein —RXC1 is —RXCC; and —RXCC is —Cl.

### Claim 308 (depends on 296)

A method according to claim 296, wherein —RXC1 is —RXCC; and —RXCC is —Cl.

### Claim 309 (depends on 293)

A method according to claim 293, wherein —RXCC is —RXCCC; and —RXCCC is -Me.

### Claim 310 (depends on 294)

A method according to claim 294, wherein —RXCC is —RXCCC; and —RXCCC is -Me.

### Claim 311 (depends on 295)

A method according to claim 295, wherein —RXCC is —RXCCC; and —RXCCC is -Me.

### Claim 312 (depends on 296)

A method according to claim 296, wherein —RXCC is —RXCCC; and —RXCCC is -Me.
